JOP20200063A1 - صور متغيرة لجسم مضاد - Google Patents

صور متغيرة لجسم مضاد

Info

Publication number
JOP20200063A1
JOP20200063A1 JOP/2020/0063A JOP20200063A JOP20200063A1 JO P20200063 A1 JOP20200063 A1 JO P20200063A1 JO P20200063 A JOP20200063 A JO P20200063A JO P20200063 A1 JOP20200063 A1 JO P20200063A1
Authority
JO
Jordan
Prior art keywords
antibody variants
antibodies
tnf
bind
binding
Prior art date
Application number
JOP/2020/0063A
Other languages
English (en)
Inventor
Esther Maria Furrer
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59923275&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20200063(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of JOP20200063A1 publication Critical patent/JOP20200063A1/ar
Application granted granted Critical
Publication of JOP20200063B1 publication Critical patent/JOP20200063B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

يتعلق الاختراع الحالي بأجسام مضادة ترتبط بـ TNF? وتبدي ارتباط FcRn معدل. وتتميز الأجسام المضادة وفقًا للاختراع بوظائف استجابة مناعية جيدة و/أو خواص حركة دوائية.
JOJO/P/2020/0063A 2017-09-19 2020-03-17 صور متغيرة لجسم مضاد JOP20200063B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17191989.7A EP3456738B1 (en) 2017-09-19 2017-09-19 Antibody variants
PCT/EP2018/074522 WO2019057564A1 (en) 2017-09-19 2018-09-11 ANTIBODY VARIANTS

Publications (2)

Publication Number Publication Date
JOP20200063A1 true JOP20200063A1 (ar) 2020-03-17
JOP20200063B1 JOP20200063B1 (ar) 2024-12-22

Family

ID=59923275

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2020/0063A JOP20200063B1 (ar) 2017-09-19 2020-03-17 صور متغيرة لجسم مضاد

Country Status (26)

Country Link
US (2) US11999781B2 (ar)
EP (3) EP3456738B1 (ar)
JP (2) JP7240385B2 (ar)
KR (2) KR102761321B1 (ar)
CN (2) CN119409817A (ar)
AR (1) AR113303A1 (ar)
AU (2) AU2018337495B2 (ar)
BR (1) BR112020005482A2 (ar)
CA (1) CA3075959A1 (ar)
CL (1) CL2020000721A1 (ar)
CO (1) CO2020003260A2 (ar)
CR (2) CR20200132A (ar)
EA (1) EA202090617A1 (ar)
ES (1) ES2991804T3 (ar)
GE (4) GEAP202215316A (ar)
IL (2) IL320817A (ar)
JO (1) JOP20200063B1 (ar)
MA (1) MA50156A (ar)
MX (1) MX2020002989A (ar)
PH (1) PH12020500473A1 (ar)
SA (1) SA520411559B1 (ar)
SG (1) SG11202002220TA (ar)
TW (1) TWI873084B (ar)
UA (1) UA129515C2 (ar)
WO (1) WO2019057564A1 (ar)
ZA (1) ZA202001830B (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3032820A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
WO2026055315A1 (en) 2024-09-05 2026-03-12 Stirx, Inc. Humanized monoclonal antibodies, methods of making and treatment of neisseria gonorrhea

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038955T2 (hu) * 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
CN101111521B (zh) * 2004-12-29 2011-08-24 株式会社柳韩洋行 肿瘤坏死因子-α特异性人源化抗体
BRPI0518994A2 (pt) 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
KR101616758B1 (ko) * 2007-12-26 2016-04-29 젠코어 인코포레이티드 ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
RU2653753C1 (ru) * 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
US10233238B2 (en) * 2014-03-26 2019-03-19 Cell Medica Switzerland Ag TNF alpha antibody or fragment thereof and methods of use
JP2017513481A (ja) * 2014-04-16 2017-06-01 ユーシービー バイオファルマ エスピーアールエル 多量体Ｆｃタンパク質
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CN109071631B (zh) * 2016-03-14 2023-07-14 奥斯陆大学 具有改变的FcRn结合的工程化免疫球蛋白
PT3219726T (pt) * 2016-03-17 2020-12-15 Tillotts Pharma Ag Alfa-anticorpos anti-tnf e fragmentos funcionais dos mesmos

Also Published As

Publication number Publication date
IL320817A (en) 2025-07-01
PH12020500473A1 (en) 2021-01-25
KR20200053514A (ko) 2020-05-18
AU2018337495A1 (en) 2020-04-09
UA129515C2 (uk) 2025-05-21
JP7240385B2 (ja) 2023-03-15
CL2020000721A1 (es) 2020-08-07
GEP20247700B (en) 2024-11-25
CN111094343B (zh) 2024-09-20
WO2019057564A1 (en) 2019-03-28
ES2991804T3 (es) 2024-12-04
TWI873084B (zh) 2025-02-21
SG11202002220TA (en) 2020-04-29
EP4424707A2 (en) 2024-09-04
US20240343793A1 (en) 2024-10-17
CR20210205A (es) 2021-07-27
MA50156A (fr) 2020-07-29
IL273351B1 (en) 2025-06-01
EP3456738B1 (en) 2024-07-17
CN119409817A (zh) 2025-02-11
MX2020002989A (es) 2020-07-22
GEP20237484B (en) 2023-03-27
SA520411559B1 (ar) 2024-03-19
JP2023036885A (ja) 2023-03-14
KR102761321B1 (ko) 2025-02-04
GEAP202415617A (en) 2024-06-25
EP4424707A3 (en) 2024-11-13
CR20200132A (es) 2020-07-24
EP3456738A1 (en) 2019-03-20
IL273351B2 (en) 2025-10-01
ZA202001830B (en) 2024-10-30
EA202090617A1 (ru) 2020-07-27
EP3684807A1 (en) 2020-07-29
AU2024287208A1 (en) 2025-02-13
JOP20200063B1 (ar) 2024-12-22
EP3456738C0 (en) 2024-07-17
BR112020005482A2 (pt) 2020-09-29
AR113303A1 (es) 2020-04-08
CA3075959A1 (en) 2019-03-28
CN111094343A (zh) 2020-05-01
KR20250022222A (ko) 2025-02-14
US11999781B2 (en) 2024-06-04
JP7402304B2 (ja) 2023-12-20
GEAP202215316A (en) 2022-10-25
AU2018337495B2 (en) 2024-10-17
JP2020534307A (ja) 2020-11-26
IL273351A (en) 2020-05-31
TW201915021A (zh) 2019-04-16
US20200216527A1 (en) 2020-07-09
CO2020003260A2 (es) 2020-04-13

Similar Documents

Publication Publication Date Title
PH12019502282A1 (en) Bispecific antibodies specifically binding to pd1 and lag3
SA522431756B1 (ar) Tigit أجسام مضادة لـ
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
MX2019012953A (es) Anticuerpo biespecifico contra ox40 y ctla-4.
MX2022005202A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
PH12018502054A1 (en) Antibodies recognizing tau
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
PH12020550908A1 (en) Anti-cxcr5 antibodies and compositions and uses thereof
WO2016086189A3 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
WO2017120523A3 (en) Anti-pro/latent myostatin antibodies and methods of use thereof
MX2022009875A (es) Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes.
WO2017091656A8 (en) Heterodimeric antibodies that bind cd3 and cd38
PH12017502019B1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
MX2018013386A (es) Anticuerpos que reconocen tau.
EP3705494A3 (en) Antibodies against frizzled proteins and methods of use thereof
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
PH12020500473A1 (en) Antibody variants
MX2020002934A (es) Variantes de anticuerpos.
WO2018227063A8 (en) Anti-robo2 antibodies, compositions, methods and uses thereof
PH12021551470A1 (en) Antibody that binds to vegf and il-1beta and methods of use
EA202090727A1 (ru) Варианты антител
WO2014201400A3 (en) Anti-factor viii antibodies or uses thereof
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
WO2016140860A3 (en) Peptide linker for attachment of thiol-reactive molecules to surfaces